GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
The Source
TWSJ
World News
What We Know About Trump’s Pickaxe Iran Target
TWSJ·45m ago·3 min read
Business
Walmart Further Shuffles Top Executives
TWSJ·1h ago·3 min read
Business
Heineken is Trying a Heat Battery to Generate Steam for its Brewing
TWSJ·1h ago·3 min read
Business
Consumer Sentiment Climbed in July, per Michigan Survey
TWSJ·1h ago·3 min read
Related
On this beat
Health
Level 2 – Chikungunya in Costa Rica
CDC·1d ago·3 min read
Health
World’s largest olive oil company says market has ‘definitively’ entered new phase
CNBC·10h ago·3 min read
Health
Some of the first at-home blood and saliva tests measuring the level of microplastics in our bodies are on the market. Your Health columnist Sumathi Reddy tried them out.
TWSJ·14h ago·3 min read
Health
Buy the contractor before the renovation is complete: This stock’s next growth phase is taking shape
CNBC·21h ago·3 min read